WPI's Response to UK's XMRV study!

Discussion in 'Fibromyalgia Main Forum' started by karynwolfe, Jan 7, 2010.

  1. karynwolfe

    karynwolfe New Member

    Sorry if htis has alreayd been posted

    (From http://cfidsresearch.blogspot.com/2010/01/whittemore-peterson-institute-releases.html and http://www.wpinstitute.org/news/docs/WPI_Erlwein_010610.pdf respectively )


    The Whittemore Peterson Institute has released an official statement regarding the recent UK XMRV study. The position of the institute is that it basically discredits the validity of the study in whole, stating it does not even qualify as a replication study. The Whittemore Peterson Institute states that they are actively collaborating with other research groups around the world, and as well Judy Mikovits stated in a New Zealand Herald article that blood their group tested from the UK showed very similar percentages of XMRV infection in London patients as in their published study! Much like when Robert Gallo and Luc Montaigner discovered the HIV virus, other groups initially disputed their findings because they did not use the exact same methodology in their replication studies!



    Official Statement from the Whittemore Peterson Institute Regarding UK Study

    The Whittemore Peterson Institute (WPI) has reviewed the paper entitled “Failure to Detect the
    Novel Retrovirus XMRV in Chronic Fatigue Syndrome.” This study did not duplicate the
    rigorous scientific techniques used by WPI, the National Cancer Institute and the Cleveland
    Clinic, therefore it cannot be considered a replication study nor can the results claim to be
    anything other than a failure not just to detect XMRV, but also a failure to suggest meaningful

    The scientific methods used by WPI are very exact and require specific techniques to ensure
    accuracy. Differences in techniques employed by Erlwein et al. not only explain their failure to
    replicate the WPI study, but also render the conclusions meaningless. These differences
    include, but are not limited to the following:
    1) blood sample volumes and processing;
    2) patient criteria/population differences;
    3) number and type of tests done to assure accurate results, including white blood cell
    4) use of a molecular plasmid control in water versus a positive blood sample; and
    5) different primer sequences and amplification protocol used to find the virus, which
    were not validated by a clinical control.

    The WPI study was published after six months of rigorous review and three independent lab
    confirmations, proving that contamination had not taken place and that infectious XMRV was
    present in 67 percent of CFS patients diagnosed according to the Canadian and Fukuda criteria.
    In contrast, this latest study was published online after only three days of review. Significant
    and critical questions remain as to the status of patient samples used in the UK study as those
    samples may have been confused with fatigued psychiatric patients, since the UK has relegated
    “CFS” patients to psychiatric care and not traditional medical practices.

    “Little is known about the prevalence of XMRV world-wide, much less the incidence of XMRV
    in ME/CFS or prostate cancer” emphasizes Dr. Judy Mikovits. “WPI and its NCI collaborators
    are actively engaged with international research teams to investigate these important questions.”
    WPI does not recommend the use of anti-retroviral drugs that have yet to be proven to be
    effective in treating XMRV infection. However, several large pharmaceutical companies have
    expressed interest in developing anti-retroviral and immune modulating drugs that will
    effectively treat XMRV associated diseases.

    WPI looks forward to the results of other scientific groups around the world, serious about
    replicating its scientific results, by using the same techniques as WPI and its collaborators. The
    fact that XMRV was detected in 67 percent of the CFS samples in the U.S. study determined a
    significant association between XMRV and CFS, demanding a much more serious inquiry by
    responsible health agencies around the world as to the cause of this debilitating disease.

    [This Message was Edited on 01/07/2010]